Epilepsy is a common neurological disorder in the United States, affecting approximately
1.2% of the population. Some people with epilepsy may experience seizure clusters, which …

Patients with epilepsy may experience seizure clusters, which are described by the US Food
and Drug Administration (FDA) as intermittent, stereotypic episodes of frequent seizure …

Seizure clusters (also referred to as acute repetitive seizures) consist of several seizures
interspersed with brief interictal periods. Seizure clusters can break down γ‐aminobutyric …

Objective Understanding fluctuations in seizure severity within individuals is important for
determining treatment outcomes and responses to therapy, as well as assessing novel …

Abstract Sudden Unexpected Death in Epilepsy is a leading cause of epilepsy-related
mortality, and the analysis of mouse Sudden Unexpected Death in Epilepsy models is …

Objectives Dysfunctional connectivity and preexisting structural abnormalities of central
autonomic network (CAN) regions have been shown on magnetic resonance imaging (MRI) …

Abstract Objectives In October 2020 and March 2021, the US Food and Drug Administration
(FDA) classified lamotrigine as a class IB antiarrhythmic, announcing an increased risk of …

Background Changes in the neutrophil-lymphocyte ratio (NLR) has been reported to be
associated with epilepsy. Here we aim to investigate the correlation of temporal changes of …

Objective Sudden unexpected death in epilepsy (SUDEP) is a serious threat to individuals
with intractable epilepsies, contributing to premature mortality. Understanding the elusive …

Midazolam nasal spray (MDZ-NS) is a new emerging rescue medication that suppresses
epileptic seizures. Until now, few studies, pharmacokinetic (PK) and pharmacodynamic (PD) …